ReviewAntibodies (Basel, Switzerland)2015
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
Review in Antibodies (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study.Frontiers in public health · 2021Pooled it
- An overview of immunotoxicity in drug discovery and development.Toxicology letters · 2025Review
- Review
- Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies.Tissue engineering. Part C, Methods · 2023Review
- Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.Frontiers in immunology · 2023Review
- Review
- Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question.Pharmaceutics · 2022Review
- The Role of Bispecific Antibodies in Non-Hodgkin's Lymphoma: From Structure to Prospective Clinical Use.Antibodies (Basel, Switzerland) · 2022Review
- Development of combinatorial antibody therapies for diffuse large B cell lymphoma.Frontiers in medicine · 2022Article
- A Rational Designed Novel Bispecific Antibody for the Treatment of GBM.Biomedicines · 2021Article
- Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.Oncoimmunology · 2020Article
- Review
- A modular DNA scaffold to study protein-protein interactions at single-molecule resolution.Nature nanotechnology · 2019Article
- Bispecific Antibodies in the Treatment of Hematologic Malignancies.Clinical pharmacology and therapeutics · 2019Review
- Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity.Biophysical journal · 2019Article
- Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer.Antibodies (Basel, Switzerland) · 2019Review
- p95HER2-T cell bispecific antibody for breast cancer treatment.Science translational medicine · 2018Article
- Targeted Intracellular Delivery of Antibodies: The State of the Art.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the "bispecifics" market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.